• Males or females ≥ 18 years of age

• Histologically confirmed (liver biopsy within 24 previous weeks) and documented unresectable hepatocellular carcinoma

• Patients with a BCLC C or BCLC B status ineligible for or in failure of locoregional treatment, as per the Barcelona Clinic Liver Cancer (BCLC) staging system

• No prior systemic therapy for advanced HCC

• Liver tumor burden \< 50% of the liver (per Investigator judgment)

• Child-Pugh A (≤ 6) without any history of cirrhotic decompensation within the past 6 months

• Antiviral therapy required in hepatitis B virus patients (Hepatitis B antigen positive)

• Willing to have liver biopsy between C4 and C5

• Presence of a measurable tumor per RECIST v1.1 criteria

⁃ Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

⁃ Life expectancy ≥ 12 weeks

⁃ Absence of previous liver decompensation

⁃ In case of cirrhosis, last esophageal varices detection by esogastroduodenal endoscopy have to be performed within last the 6 months before inclusion

⁃ Adequate hematologic function prior to the first dose of NP137, defined as:

⁃ Absolute neutrophils count ≥ 1500 cells/μL 14.2. Hemoglobin ≥ 9 g/dL with no transfusion within 4 weeks prior to first planned dose of NP137 14.3. Platelet count \> 50,000/μL with no transfusion within 2 weeks prior to first planned dose of NP137

⁃ Adequate renal function prior to first dose, defined as:

‣ 1. Serum creatinine \< 1.5 × Upper limit of normal (ULN ) 15.2. Creatinine clearance ≥ 30 mL/min/m2 (by Cockroft-Gault equation of 24-hour urine) if creatinine ≥ 1.5 × ULN

⁃ Adequate hepatic function prior first dose, defined as AST/ALT ≤ 5 × ULN

⁃ Women patients of childbearing potential must have a negative serum pregnancy test at screening and baseline, and be willing to use a highly effective contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for \> 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential.

⁃ Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration.

⁃ Amenable to computed tomography (CT) with 3 or 4 phase liver or magnetic resonance imaging (MRI) of abdomen and pelvis, and CT of chest, or MRI of whole body, for initial tumor size measurements and subsequent follow-up.

⁃ Absence of other clinically relevant abnormalities for any screening laboratory test results as judged by the Investigator and Sponsor.

⁃ Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

⁃ Able to understand and provide written informed consent

⁃ Patients covered by Health Insurance System